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PAL1
DETERMINING THE MINIMAL CLINICALLY IMPORTANT
DIFFERENCE FOR THE ESPRINT-15 QUESTIONNAIRE FOR
PATIENTS WITH ALLERGIC RINHITIS
Baro E1, On Behalf of Esprint Study Investigators2
13D Health Research, Barcelona, Spain; 2Esprint Study Investigators
Group, Barcelona, Spain
OBJECTIVE: To determine the minimal clinically important dif-
ference (MCID) for improving interpretation of the recently val-
idated Esprint-15 questionnaire, to measure health-related
quality of life for patients with allergic rhinitis. METHODS: An
observational multicenter study was carried out with allergic
rhinitis patients to validate the Esprint questionnaire (15 items
of symptoms, daily life activity, sleep and psychological impact).
It uses 7-point response options. Global score range from zero
(worse) to 5.8 (better). MCID was determined by applying the
method previously used by Juniper et al. (1996) in the case of
the Rhinoconjuntivitis Quality of Life questionnaire. Patients
completed twice the Esprint-15 and assessed their change on
health status in a 13-point scale from -6 (a very great deal worse)
to 0 (no change) to +6 (a very great deal better). Patients were
classiﬁed as “no change” (-1, 0 or +1), “MCID” (+3 or +2),
“moderate change” (+4 or +5) and “large change” (+6).
RESULTS: Valid responses for the 2 visits were obtained from
245 patients (mean age 32, 62.2% women, average of moderate
symptoms at inclusion, mean 7 years from diagnosis, 58% were
following AR treatment) of which: 30 (12.2%) reported “large
change”, 86 (35.1%) reported “moderate change”, 55 (22.4%)
reported “MCID”, 48 (19.6%) reported “no change” and 25
(10.2%) reported deterioration in health status. Mean (SD)
increases in the Esprint-15 global score were: 0.2 (0.9) for
patients with “no change”, 1.1 (0.9) for patients at the “MID”,
2 (1.1) for patients reporting “moderate change”, and 2.9 (1.2)
for patients reporting “large change”. Because of the small
sample size, results for patients reporting negative changes are
not presented, although they suggest an attenuate but similar ten-
dency. CONCLUSION: There is evidence that mean positive
changes in global score from Esprint-15 questionnaire of about
1 or more may be considered of clinical importance.
PAL2
ATTRIBUTES FOR PREFERENCE OF NEW FAST DISSOLVING
TABLET (FDT) FORMULATION OF EBASTINE IN PATIENTS
WITH ALLERGY
Roger A1, Fortea J2, Artes M3, Montilla L3
1Centre Roger Barri d’Asmologia i Al.lèrgia, Barcelona, Spain;
2Laboratorios Almirall, Barcelona, Spain; 3Adelphi Targis, S.L, Barcelona,
Spain
OBJECTIVE: The main objective of the research is to understand
the perceived key attributes and strengths of the FDT formula-
tion of Ebastine. METHODS: The new formulation Ebastine
FDT was tested using placebo both in patients (60) and physi-
cians (82) throughout qualitative face-to-face interviews in
Belgium, France, Finland, Germany and Italy. Patients suffering
from chronic or acute/seasonal allergies regularly taking pre-
scription antihistamines and physicians who are high prescribers
of antihistamines were included. RESULTS: The key attributes
for preference of the new FDT formulation are convenience and
ease of use (can be taken everywhere, not water is needed) and
the perception of faster onset of action. After tasting there’s a
positive evaluation for the majority (57 patients out of 60 and
75 physicians out of 82) on most FDT formulation attributes
(correct texture, appearance, colour and size and very rapid dis-
solving). Taste evaluation was controversial (mint ﬂavour) and
patients difﬁculties handling the blister disappeared when
instructed. The FDT formulation is perceived as suitable for any
type of patients, particularly those with acute episodes, active
lifestyle, difﬁculties to swallow and gastrointestinal problems
according to patients; and those with an active lifestyle accord-
ing to physicians. Most patients consider that the new formula-
tion can improve compliance (45 out of 60). The likelihood of
taking/prescribing Ebastine FDT is quite high, rating 7.9 (4.2)
and 7.6 (5.7) respectively for patients and physicians on a 1–10
scale (1–7 scale in Finland). Most patients (47 out of 60) and
physicians (54 out of 82) preferred the new FDT formulation.
CONCLUSIONS: The new FDT formulation is preferred by
both physicians and patients, because it’s easier to comply, more
convenient and it’s associated with a perception of faster onset
of action.
PAL3
DEVELOPMENT, PILOT TESTING, SCORING AND VALIDATION
OF A MANAGEMENT TOOL FOR PATIENTS UNDERGOING
SPECIFIC IMMUNO-THERAPY
Arnould B1, Benmedjahed K2, Fadel R3, Bos C3, Fontaine JF4,
Haddad T5, Mathelier Fusade P5, Ruﬁn P5, Saint Martin F6, Zekri J7,
Viala M2
1Mapi Values, Lyon, Rhone, France; 2Mapi Values, Lyon, France;
3Stallergènes, Antony, France; 4Private practice, Reims, France; 5Private
practice, Paris, France; 6Private practice,Villebon sur Yvette, France;
7Private practice,Toulouse, France
OBJECTIVE: Clinicians in charge of allergic rhinitis patients
miss speciﬁc questionnaires assessing patients’ expectations, sat-
isfaction, adherence, persistence, attitudes toward Speciﬁc
Immuno-therapy (SIT). Our aim was to provide them with a spe-
ciﬁc instrument allowing bettering adapting care to the patient’s
characteristics, perceptions and behaviour. METHODS: A con-
ceptual model was identiﬁed from a literature review, 5 clinician
and 21 patient interviews. A test version of the questionnaire was
developed and independently validated by an Advisory Com-
mittee (AC). Five patients suffering from allergic rhinitis and
treated by SIT completed the questionnaire and were asked to
comment the questionnaire in-depth. It was redrafted and
included in a pilot study (10 clinicians, 30 patients) in real con-
ditions of use. A revised questionnaire was administrated by 211
clinicians to 571 patients (380 having a SIT and 191 about to)
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between February and May 2005 in a cross-sectional, obser-
vational study. RESULTS: Fourteen global and 57 detailed 
concepts were included in the conceptual model. The test ques-
tionnaire contained 64 items. After cognitive debrieﬁng, 7 items
were excluded. The questionnaire was well-accepted by the
patients in the pilot study. Clinicians were delighted to have a
helpful patient-management tool. The pilot questionnaire con-
tained 52 items in 10 sections (symptoms, allergy in daily life,
motivations for SIT, advantages, constraints, intake, outcomes,
satisfaction, intention, information). The majority of the 211
clinicians reported high patient acceptability and major interest
in using the questionnaire routinely. The items presenting missing
data, not clearly related to a speciﬁc domain, or redundant were
not selected for ﬁnal format and score calculation. The scores
were assessed for internal consistency reliability, construct valid-
ity and predictive validity. CONCLUSION: This instrument
covers the major domains impacting the patient’s persistence in
SIT. It is a promising patient-management tool for use in clini-
cal practice.
ARTHRITIS
PAR1
COSTS AND EFFECTS OF CELECOXIB IN THE TREATMENT
OF PATIENTS WITH RHEUMATOID ARTHRITIS AND
OSTEOARTHRITIS IN THE NETHERLANDS
Al M1, Janssen M2, Monteban HC3
1Institute for Medical Technology Assessment, Rotterdam,The
Netherlands; 2Rijnstate Hospital, Arnhem,The Netherlands; 3Pﬁzer bv,
Capelle a/d IJssel,The Netherlands
OBJECTIVE: To assess the balance between costs and upper 
GI side effects of treatment with celecoxib (a COX-2 speciﬁc
inhibitor) compared with nonspeciﬁc NSAIDs alone, nonspeciﬁc
NSAIDs plus misoprostol, nonspeciﬁc NSAIDs plus histamine-2
receptor antagonists (H2RA), nonspeciﬁc NSAIDs plus proton
pump inhibitors (PPI), and Arthrotec, in The Netherlands.
METHODS: A model was used to convene data from various
sources. The probabilities of GI side effects for celecoxib and
nonspeciﬁc NSAIDs alone were derived from trial data, while 
all other probabilities were derived from published sources.
Resource use was derived from databases and an expert panel.
Calculations were based on 6 months of treatment, and were
from a societal perspective but were limited to direct medical
costs (2004 Euros; €). Distinction was made between risk groups
based on risk factors such as older age, use of corticosteroids
and history of GI events. RESULTS: Treatment with celecoxib
was associated with the lowest number of GI side effects and
related deaths. Assuming an average patient, the total costs per
6 months of therapy were: celecoxib €212, nonspeciﬁc NSAIDs
alone €151, NSAIDs plus misoprostol €227, NSAIDs plus
H2RAs €268, NSAIDs plus PPIs €269, and Arthrotec €171.
Incremental costs per life-year saved for celecoxib compared
with nonspeciﬁc NSAIDs alone were €12,417 for all patients,
and -€760 for high-risk patients. Comparing celecoxib and
Arthrotec, the incremental costs per life-year saved were €32,757
for all patients and €7759 for those at high-risk of GI events.
CONCLUSION: Celecoxib is a more effective and less costly
treatment than nonspeciﬁc NSAIDs plus misoprostol, NSAIDs
plus H2RAs, and NSAIDs plus PPIs. It is cost-effective compared
with nonspeciﬁc NSAIDs alone for patients at medium- to high-
risk of GI events, and also for high-risk patients. Compared with
Arthrotec, celecoxib showed an improving cost-effectiveness
proﬁle with increasing GI risk.
PAR2
METAL ON METAL (MOM) HIP RESURFACING (BIRMINGHAM
HIP RESURFACING (BHR)) IN YOUNG PATIENTS WITH
SEVERE HIP DAMAGE—A COST UTILITY ANALYSIS
Richardson JB1, Band T2, Barnes DC1, Buckland AG3, Posnett J4
1RJAH Orthopaedic & District Hospital NHS Trust, Oswestry,
Shropshire, UK; 2Smith & Nephew Orthopaedics Ltd, Birmingham,
UK; 3Abacus International, Bicester, Oxfordshire, UK; 4Smith &
Nephew Wound Management, Hull, UK
OBJECTIVES: Total Hip Replacement (THR) is regarded as gold
standard treatment for degenerative hip disease in elderly
patients. Young, active patients, however, are a more challeng-
ing group for THR due to the high risk of revision and associ-
ated complications. In 2002, the National Institute for Health
and Clinical Excellence (NICE) recommended MoM hip resur-
facing as a treatment option for this patient group. An alterna-
tive treatment for these patients is watchful waiting (WW)
whereby patients are maintained on drug-based regimens until
they are old enough to warrant a THR. The aim of this study
was to evaluate the cost-effectiveness of BHR vs. WW in 45–55
year old patients with severe hip damage. For completeness the
cost-effectiveness of BHR vs. THR was assessed in the same
patient group. METHODS: A health economic model was con-
structed to assess the efﬁcacy, cost and health-related quality of
life associated with BHR, WW and THR treatments. Efﬁcacy
data for BHR were obtained from a large, prospective database
(n = 4424), which provided up to 5 years follow-up for individ-
ual BHR patients. Resource use and utility data were obtained
from published sources. The primary outcome from the model
was the cost per quality-adjusted life-year (QALY). RESULTS:
Preliminary results demonstrate that at year 5 BHR has an incre-
mental cost/QALY (ICER) of £1,101 compared to WW and an
ICER of £13,125 compared to THR. Over time the ICER
decreases and BHR becomes dominant (i.e. it is more effective
and costs less) compared to WW and THR by year 20 and 15,
respectively. CONCLUSIONS: This study demonstrates that in
patients aged 45–55 years with severe hip damage, BHR offers
an extremely cost-effective alternative to WW with an equiva-
lent improvement in quality of life to THR. Patients treated with
BHR will beneﬁt from signiﬁcant health gains at an acceptable
cost.
PAR3
PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS
SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT
MODERATE TO SEVERE OSTEOARTHRITIS (OA) PAIN OF THE
HIP/KNEE
Marshall DA1, Strauss ME2, Pericak D1, Buitendyk M1, Codding C3,
Torrance G1
1Innovus Research Inc, Burlington, ON, Canada; 2Purdue Pharma L.P,
Stamford, CT, USA; 3Oklahoma Sports, Oklahoma City, OK, USA
OBJECTIVES: OA is associated with signiﬁcant disability,
reduced productivity, decreased HRQoL, and increased health
care costs. The objective was to evaluate the cost-effectiveness of
controlled-release oxycodone (CRO) from a societal perspective
incorporating time loss (paid and unpaid work for patients and
friends/relatives). METHODS: Open-label, active-controlled,
randomized, naturalistic 4-month study of effectiveness and 
cost-effectiveness of CRO vs. short-acting opioids. Outcomes,
resource utilization and time loss were collected by telephone.
Quality-adjusted-life-years (QALYs) were calculated from HUI3
scores. Cost-effectiveness was measured as cost/QALYs gained
and cost/patient improved. RESULTS: Patients treated with
CRO compared to short-acting opioids were more productive
